The Clinical Efficacy of Cytokine- induced Killer Cells on Genitourinary System Tumor

Objective To observe the cytotoxic activity in vitro of cytokine-induced killer cells(CIK cells),and to observe the short-term clinical efficacy,immunological activity and side effects of CIK cells in treating genitourinary system tumor.Methods A total of 10 patients with genitourinary system malignancies were recorded with CIK cell therapy from July 2007 to March 2010.Peripheral blood mononuclear cells(PBMC)from patients with standard treatment protocols were induced to CIK cells in vitro,then phenotype of CIK cells was observed and in vitro cytotoxicity was measured by MTT method.All patients received a certain dose of CIK cells in adoptive immunotherapy and the recent clinical efficacy,immune response and adverse effects were observed.Results Cytotoxic activity of CIK cells in vitro result showed that the anti-ratio was 93.59±6.69 and 76.78± 14.23 respectively when the ratio of effector cell to target cell was 16:1and 8:1.In the recent clinical efficacy evaluation,2 cases of prostatic carcinoma got better remission,the levels of specific prostatic antigen and free antigen in one case decreased after treatment;all of 4 cases of renal cancer got complete remission,the levels of AFP and CEA in 1 case of SF decreased to normal levels;3 of 4 cases of bladder cancer got partial remission.The cells surface markers CD3+,CD4+,CD8+ of patient’s PBMC had increased(P 0.05) compared with that before transfusion,which means patient's specific immune response was induced by CIK cells.No adverse reaction was observed during the infusion of CIK cells for the 10 patients.Conclusion In genitourinary system tumor immunotherapy,CIK cells can induce specific immune response and are also newanti-tumor effector cells,which have good clinical efficacy.